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Abstract
Determining the biliary clearance of drugs in humans is very challenging because bile in not readily
accessible due to the anatomy of the hepatobiliary tract. The collection of bile usually is limited to
post-surgical patients with underlying hepatobiliary disease. In healthy subjects, feces typically are
used as a surrogate to quantify the amount of drug excreted via non-urinary pathways. Nevertheless,
it is very important to characterize hepatobiliary elimination because this is a potential site of drug
interactions that might result in significant alterations in systemic or hepatic exposure. In addition
to the determination of in vivo biliary clearance values of drugs, the availability of in vitro models
that can predict the extent of biliary excretion of drugs in humans may be a powerful tool in the pre-
clinical stages of drug development. In this review, recent advances in the most commonly used in
vivo methods to estimate biliary excretion of drugs in humans are outlined. Additionally, in vitro
models that can be employed to investigate the molecular processes involved in biliary excretion are
discussed to present an updated picture of the new tools and techniques that are available to study
the complex processes involved in hepatic drug transport.
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INTRODUCTION
With the advent of combinatorial chemistry, an increasing number of new chemical entities
that are more lipophilic and characterized by high molecular weight are being synthesized and
screened during the drug discovery process.1 Drugs with these physicochemical characteristics
often are associated with significant hepatic metabolism and/or excretion via the biliary route.
2,3 The threshold molecular weight for drugs and metabolites to be excreted preferentially into
bile varies between species, ranging from ~235 in rats up to 500–600 in humans. Biliary
excretion of compounds can significantly impact the systemic exposure, pharmacological
effect and toxicity of certain drugs. Drugs excreted into bile often undergo some degree of
reabsorption along the gastrointestinal tract (e.g., mycophenolic acid4, warfarin5, and
digoxin3). Enterohepatic recycling is also a very important physiological process for bile salt
homeostasis. In humans, the intestinal reabsorption of bile salts is very efficient; more than
95% of the bile salt pool is reabsorbed in the distal ileum.6,7 So far, limited in vivo information
has been available regarding the extent of biliary elimination of drugs and metabolites in
humans, primarily due to the difficulty in obtaining bile samples from healthy human subjects.
An accurate measure of biliary clearance and of the extent of biliary excretion of compounds
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would be extremely valuable in evaluating the contribution of biliary clearance to total systemic
clearance, elucidating potential mechanisms of hepatobiliary toxicity, predicting drug-drug
interactions, and identifying enterohepatic versus enteroenteric recirculation. Several clinical
studies have shown that drug-drug interactions can result in changes in drug absorption due to
inhibition of transport proteins [increased exposure to talinolol after P-glycoprotein (P-gp, gene
symbol ABCB1) inhibition8, or inhibition of intestinal secretion resulting in improved
therapeutic efficacy of paclitaxel9]. Important modifications in the pharmacokinetics/
pharmacodynamics of digoxin, another P-gp substrate, have been observed with co-
administration of other P-gp substrates/inhibitors, which are thought to cause interactions in
intestinal10, biliary11,12 and/or renal13,14 levels. However, drug-drug interactions
influencing biliary clearance of compounds have not been investigated systematically due to
technical difficulties in performing these experiments in humans. The inhibition of
hepatobiliary transport processes can affect the ability of the liver to extract bile salts from the
bloodstream or, potentially more importantly, can affect the metabolism and biliary excretion
of bile salts. Although mechanisms of hepatotoxicity are believed to be multifactorial, it has
been demonstrated that inhibition of bile salt biliary excretion by drugs (e.g., troglitazone15
and bosentan16) can affect hepatocyte viability due to the accumulation and direct toxicity of
detergent-like bile salts.17
The contribution of biliary excretion to the overall disposition and pharmacological effect of
some drugs has been underestimated due to the lack of methodologies to accurately quantify
the amount of drug subjected to enterohepatic recirculation, and a poor understanding of the
processes involved in hepatic excretion and reabsorption of drugs from the canalicular space,
bile ducts and intestine. Several animal models, primarily rodent, have been used to study
genetic diseases affecting biliary clearance and drug-drug interactions. Mouse and rat isolated
perfused liver experiments and bile duct cannulated animals are useful tools for studying biliary
disposition of drugs in the early phases of drug development. The availability of rodent models
genetically deficient in specific transport proteins has improved understanding of the complex
molecular processes involved in excretion of endogenous and exogenous compounds into bile.
18–22 However, accumulating evidence suggests that significant inter-species differences exist
in the function and regulation of transport proteins, in addition to the already thoroughly
characterized species differences in metabolism; these findings complicate the direct
extrapolation of animal data to humans.23–25 Enterohepatic recirculation of drugs has been
studied extensively in experimental animals where cannulation of the bile duct allows for
interruption of bile flow into the intestine. The importance of enterohepatic recirculation also
has been investigated with a similar study design in humans. The pharmacokinetic profiles of
drugs have been compared in patients with bile duct obstruction, before and after removal of
nasobiliary drainage. This design allows complete collection of bile and interruption of
enterohepatic recirculation while the drainage is in place.26 However, since the subjects
studied in this type of experimental design are affected by hepatobiliary disease, it is not
possible to account for changes in the hepatobiliary tract that might have followed the resolution
of bile duct obstruction.
Mechanisms for Excretion of Endogenous and Exogenous Compounds into Bile
Several recent reviews have been published on the transporters involved in hepatobiliary
disposition of drugs and bile salts.27–31 The liver (Figure 1) plays a central role in the
biotransformation and removal of xenobiotics and endogenous compounds from the blood.
While the majority of small, lipophilic compounds enter the hepatocyte from the Space of Disse
on the basolateral membrane by simple passive diffusion, more polar and bulky molecules
require transport systems to cross the sinusoidal membrane (Figure 2 A). Once inside the
hepatocyte, compounds can be transported into bile either unchanged or as more hydrophilic
metabolites after phase I and/or phase II biotransformations, or can be excreted into blood by
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basolateral transport proteins (Figure 2 B). The presence of several transport proteins on the
canalicular domain of hepatocytes results in the excretion of solutes into the bile canaliculi,
which are dilated intercellular spaces. One of the many functions of the liver is the synthesis
of bile acids from cholesterol32. The major bile acids present in human bile are cholic and
chenodeoxycholic acids conjugated with glycine and taurine.33 Bile salts are excreted into bile
by the bile salt export pump (BSEP/ABCB11, Figure 2 B). Bile salts facilitate the absorption
of nutrients in the intestine by emulsifying lipophilic molecules due to their surfactant
characteristics.34 Once this function is served, bile salts are very efficiently reabsorbed into
the cells of the distal ileum by the apical sodium-dependent bile salt transport protein (ASBT/
IBAT/SLC10A2 35) and excreted across the basolateral membrane into portal blood by the
recently identified organic solute transport proteins OST α and β.36,37 In addition to bile salt
transport, hepatic transport proteins facilitate excretion of end-products of metabolism, such
as bilirubin and/or xenobiotics, into bile for subsequent removal via the intestine, and thus act
as an important clearance mechanism.
Bile Formation and Excretion
Bile formation includes uptake of bile components from the sinusoidal blood and secretion of
these substances into the canalicular space. Water and other small ions also diffuse into bile
due to the differential osmotic pressure between bile and the hepatocyte cytoplasm.
Subsequently, bile is drained into the biliary tree along the liver lobules and reaches the hepatic
ducts. In humans, a fraction of this hepatic bile is secreted continuously into the duodenum
while the majority of the ~800 mL of bile secreted per day is concentrated and stored in the
gallbladder (Figure 1). Bile freely flows into the gallbladder, because this organ has a much
lower internal pressure than the intra-hepatic ducts, common bile duct and the Sphincter of
Oddi (Figure 1). The gallbladder fills to its maximum capacity (40–70 mL) in approximately
6 hours, while re-absorbing water and electrolytes from hepatic bile.3,38–40 After ingestion
of a meal, fats, proteins and acid reach the duodenum and endogenous neurohormones such as
cholecystokinin (CCK) and secretin are released by endocrine cells in the small intestine.41
CCK, acting on the CCK-A type receptors of smooth muscle fibers, contracts the gallbladder
and relaxes the Sphincter of Oddi. A similar effect can be obtained by intravenous infusion of
physiological amounts of CCK analogs (e.g., CCK-8).42,43 CCK blood concentrations are
decreased to minimal values during fasting, which promotes contraction of the Sphincter of
Oddi and relaxation of the gallbladder walls, facilitating storage of bile in the gallbladder. CCK
also delays gastric emptying in order to coordinate the digestive postprandial process. In the
blood of humans and animals, CCK-33, 8 and 58 are the predominant active forms of this
polypeptide 44 generated by differential post-translational modifications of the same gene;
functional activity is dependent upon the last seven amino acids at the carboxyl terminus. In
addition to the role of CCK in gallbladder contraction, CCK also functions as a neurotransmitter
in the cerebral cortex to regulate satiety, and on the peripheral nerves of the GI tract to regulate
bowel movement.45,46
Methods Used to Determine In Vivo Biliary Clearance
Several preclinical tools involving in vivo or ex vivo rodent models can be utilized to evaluate
the extent of biliary excretion of drugs and the interaction of xenobiotics with bile salt transport
proteins. These tools employ animal species with well characterized differences from humans,
making the prediction/extrapolation to humans less accurate.47 Determination of the extent of
biliary excretion can be attained in human subjects with different methodologies as described
in detail below. However, only a few studies have been performed in vivo in humans to evaluate
biliary clearance of drugs, and little is known about the contribution of biliary clearance to the
overall systemic clearance for most drugs. Table I summarizes those studies published in the
literature along with the techniques used for the determination of the amount of drug and
metabolites excreted into bile.
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I. Patients as Study Subjects—Historically, there has been little success in the
development of valid and reliable techniques to quantify biliary excretion of drugs or
endogenous compounds in healthy human volunteers. Such data is obtained more easily from
patients diagnosed with diseases of the gallbladder and biliary tract who require medical
procedures that allow measurements of drug concentrations in bile. Usually these patients
suffer from cholestasis and/or occlusion of the biliary or cystic ducts, and some may have
undergone liver transplantation.
i. Cholecystectomy: Several groups have investigated gallbladder bile concentrations and
disposition of drugs into bile by administering the compound of interest to patients prior to
cholecystectomy. Drug concentrations in the gallbladder bile and tissue after removal are
quantified and compared to the plasma concentrations. Although this approach only allows the
determination of drug content in bile and tissue at a single time point, it is still very useful and
has been employed to establish whether an antibiotic reaches the necessary therapeutic
concentrations to treat bacterial infections of the gallbladder and biliary tract.48,49
ii. T-tube: Patients that require a temporary bile shunt (T-tube) that diverts part of the bile
flowing from the liver to a transcutaneous port for external collection have been employed
commonly to study biliary excretion of drugs. T-tubes are used primarily in patients with
cholangitis, distal bile duct obstruction or edema, and often are inserted after cholecystectomy
and choledochotomy. T-tubes allow for partial collection of liver bile, and provide an estimate
of the biliary excretion of administered drugs during the time that the shunt is in place.50–55
A limitation of this technique is that bile collection in these patients is not complete.
Furthermore, the composition of bile may be very different in patients due to underlying
hepatobiliary disease.56
iii. Nasobiliary Drainage: Patients with bile duct stenosis can be treated with the temporary
insertion of a nasobiliary tube. This patient population has been recruited less frequently for
drug disposition studies, probably due to the fact that this procedure is relatively new. This
intervention theoretically allows for complete collection of bile while the tube is in place. The
nasobiliary drainage interrupts delivery of bile into the duodenum and can be used to evaluate
the influence of enterohepatic recirculation on the plasma concentration-time profile for the
drug of interest. In these studies, the same patients have been used as their own control when
the stricture has resolved and the tube has been removed thus restoring the enterohepatic
recycling process.26,50
Less commonly, bile has been collected from patients equipped with other types of drainage
devices such as biliary-enteric diversions or percutaneous transhepatic cholangiodrainage.51
Although the details of the surgical procedures are beyond the scope of this review, all these
techniques allow free access to partial or complete collection of hepatic bile from patients.
In recent years laparoscopic cholecystectomy with duct exploration and endoscopic retrograde
cholangiopancreatography (ERCP) have largely replaced more invasive methods for removing
common duct stones. As a result, many fewer patients with T-tubes have been available to
enroll in studies examining the biliary excretion of drugs. The relatively few patients who are
treated with nasobiliary drainage are seldom well enough or maintain the tube long enough to
be suitable study candidates.
II. Healthy Volunteers as Study Subjects—One of the major limitations of the
techniques described above is the use of subjects with significant hepatobiliary disease. Disease
status may significantly influence transport protein expression, function, localization and/or
bile flow, thereby altering drug excretion and reabsorption patterns.57,58 It is well known that
biliary obstruction decreases the expression of BSEP and MRP2 (ABCC2) in hepatocytes, and
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increases P-gp, MDR3 (ABCB4) and MRP3 (ABCC3) expression.59,60 Moreover, cholestatic
syndromes may be associated with genetic polymorphisms in transport proteins.61,62 More
relevant information may be obtained by enrolling healthy volunteers as study subjects. In this
case, the physiology of the hepatobiliary tract is intact and healthy. However, the collection of
bile from the gallbladder or upon immediate secretion into the intestine is more challenging,
due to the difficulty of accessing the gallbladder and the anatomy of the human hepatobiliary
tract.
i. Fecal Recovery: The approach most commonly used in the determination of biliary excretion
as a route for drug elimination is the quantification of the drug of interest in feces. Often these
studies are performed with a radiolabeled compound in order to increase the selectivity and
the recovery of drug and unknown metabolites, resulting in good mass balance.63–69 More
recently, sensitive analytical techniques such as HPLC coupled with mass spectrometry have
been applied widely to the analysis of biological matrices to identify the excretion routes of
parent drugs and metabolites. Several drawbacks are associated with the quantification of drugs
in feces. Most importantly, this method does not distinguish between biliary excretion and
intestinal secretion processes. For orally administered drugs, this method does not distinguish
between unabsorbed drug and that secreted by the liver and/or gut back into the intestinal
lumen, thus, the percentage of the dose in feces does not necessarily reflect the dose excreted
into bile. Moreover, relatively unstable drugs, or compounds that are transformed into unstable
metabolites, may not be recovered in feces due to the long exposure to the intestinal contents
and colonic flora. Finally, drugs subjected to entero-hepatic or entero-enteric recycling, such
as glucuronide conjugates, can be reabsorbed in the colon upon intestinal degradation by β-
glucuronidases of the microbial flora, and will not be recovered in the feces.
ii. Aspiration of Duodenal Fluids: An ideal methodology would provide information on the
amount of parent drug and metabolites excreted into bile, and would be flexible enough to
allow for studies examining potential drug-drug interactions. This type of information can be
obtained by sampling duodenal fluids to collect bile upon discharge from the biliary tract into
the small intestine.11,12,70,71 Duodenal bile is representative of gallbladder bile in terms of
bile composition, although it is more dilute.72 The use of oroenteric tubes to withdraw
pancreatico-biliary secretions from the duodenum is a common practice in the medical field,
and has been used to study the biliary excretion of endogenous compounds such as radiolabeled
bile acids.35,73 Some of these investigations have utilized occlusive balloons to facilitate more
complete bile collection, along with the perfusion of a marker to evaluate leakage of bile or
duodenal fluids distal to the balloon seal.74 Other groups have corrected for any incomplete
bile collection by perfusing non-absorbable markers, such as polyethylene glycol or
sulphobromophthalein, into the duodenum.71,75,76 Modified versions of these methodologies
have been applied successfully to the determination of intestinal absorption and secretion of
drugs, thus enhancing the knowledge regarding intestinal processes, which complements
information acquired regarding biliary excretion of drugs.77–82 All the methods cited are
particularly sophisticated, and the execution of these studies is not trivial. These clinical studies
often require custom-made catheters, specialized personnel and equipment, and they need to
be approved by local Institutional Review Boards and Research Ethics Committees. For these
reasons, these methods are not used widely. Although a direct comparison of methods has not
been published, it is reasonable to believe that the information obtained is, in many cases, an
estimate of the amount of drug excreted via the biliary route. Nevertheless, many of the studies
conducted in healthy human volunteers have resulted in incomplete and highly variable
recovery of compounds excreted in bile. This is primarily due to the difficulty in obtaining and
assessing the completeness of bile collection, and an inherent lack of control over gallbladder
contraction. A novel method to increase the recovery of biliary secretions and correct for the
degree of gallbladder contraction, with the intention of reducing the level of complexity of the
procedure, has been developed recently by our group.83 This method assures the quantitative
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collection of bile secreted into the duodenum by temporary occlusion of the intestine with an
inflatable balloon. At the same time, the administration of a hepatobiliary imaging agent (e.g.
Tc-99m mebrofenin) is used to evaluate the degree of gallbladder contraction in response to
pharmacological stimulation, and to detect any leakage of bile due to partial occlusion of the
intestine. One of the major factors affecting the variability in the determination of biliary
excretion in humans is related to differences in the amount of bile and drug delivered into the
duodenum during the collection interval. Partial spontaneous contractions of the gallbladder
during fasting are not uncommon, and can deliver over 25% of total gallbladder bile into the
intestine. To obtain more complete gallbladder contraction, CCK-8 can be administered
intravenously to pharmacologically stimulate gallbladder emptying. CCK-8 administered at a
low dose (0.02 μg/Kg) infused slowly over 30–60 min has been reported to provide the most
complete gallbladder contraction43; however, inter-individual response is variable, and
possibly influenced by the collection procedure. Therefore, it is important to assess the degree
of gallbladder contraction in each subject. The administration of trace amounts of a gamma-
emitting probe that accumulates quickly in bile, such as Tc-99m mebrofenin, can assist in the
determination of the overall gallbladder response, and indicate when intestinal occlusion is not
complete. Alternatively, ultrasound may be used to determine the extent of gallbladder
contraction together with perfusion of the occluded tract with a non-absorbable marker to
identify leakages. A gallbladder ejection fraction (EF) can be calculated from the abdominal
gamma images of the volunteers during gallbladder contraction, and this number can be
incorporated as a correction factor when determining the amount of bile (containing drug)
excreted into the duodenum and collected by aspiration.83 This method has been shown to
correct reasonably well for the high variability in the gallbladder contraction which influences
the amount of drug excreted into the duodenum.84 Quantification of parent drug and
metabolites in bile aspirated directly from the duodenum rather than in feces can be extremely
advantageous in the identification of unknown metabolites, uniquely formed in humans, that
are unstable and would not be found after prolonged contact with intestinal enzymes (such as
unstable glucuronides).
Finally, the possibility of repeating a pharmacokinetic study in the same volunteers with and
without the balloon inflated enables an evaluation of the importance of biliary excretion in
systemic drug exposure, and in studying the enterohepatic recirculation process.85 Biliary
excretion and intestinal reabsorption may be one explanation for multiple peaks in the plasma
concentration-time profiles of some drugs.86,87 Often, pharmacokinetic modeling of these
data with a model that incorporates enterohepatic recycling has been used to explain these
experimental observations.88 Unfortunately, this approach does not provide direct evidence
for biliary excretion, and does not allow for precise quantification of the biliary clearance
parameter. Experimentally, the pharmacokinetic disposition of drugs and glucuronide
conjugates have been compared in patients before and, upon removal of nasobiliary drainage,
after the restoration of enterohepatic recirculation.26 Other studies have interrupted
enterohepatic recirculation with antibiotics, to eliminate the colonic flora, and/or
cholestyramine, a resin that prevents the availability of lipophilic compounds for absorption
in the gut lumen.4,89 Improved methods for studying drug disposition in healthy volunteers
in the presence or absence of enterohepatic recirculation should enable the investigation of
hepatobiliary disposition mechanisms in much more depth than what has been attempted to
date.
Methods Used to Determine In vitro Biliary Excretion
Several in vitro models are available to investigate the processes governing biliary excretion
and potential interactions of drugs with the hepatic uptake and excretion of bile salts and other
endogenous and exogenous substances. These tools span from the whole hepatocyte to
membrane vesicles prepared from cell lines transfected with specific transport proteins. Such
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techniques complement human and animal in vivo studies, and allow characterization of
transport processes at the molecular level. Unfortunately, the results obtained with in vitro
models are difficult to compare to human in vivo data. This is primarily due to the fact that the
data generated in vitro are used to determine values for the intrinsic biliary clearance of a drug.
In contrast, in vivo studies often are designed to obtain more crude estimates such as the
percentage of the dose excreted into bile rather than pharmacokinetic parameters. The in
vivo biliary clearance values in humans usually are not reported (Table I). Whole liver
perfusion, a common technique in rodent models to obtain biliary clearance values, is rarely
possible in humans due to limited availability of viable whole human livers.
i. Sandwich-Cultured Hepatocytes—Primary hepatocytes isolated from humans and
animals are useful tools for studying hepatic metabolism and transport due to the expression
of the full array of proteins involved in these processes. In conventional culture, a rapid decline
in expression of both metabolizing enzymes and transport proteins occurs over time after cell
isolation.90 In addition, collagenase digestion of liver, required for hepatocyte isolation results
in the disruption of the canalicular membrane and consequently, the cellular internalization of
transport proteins expressed at this membrane.91 A novel in vitro model system using primary
hepatocytes from various species, including rat and human, cultured in a collagen-sandwich
configuration (SC) has several distinct advantages over conventional hepatocyte culture. For
example, SC hepatocytes develop functional and extensive bile canalicular networks, acquire
and maintain normal cell polarity, and allow direct access to the hepatocyte and adjacent biliary
compartment.92–96 Thus, hepatocytes maintained under these culture conditions offer a
unique opportunity to study basolateral uptake and canalicular efflux transport processes.
Using simple alterations in buffer components, accumulation of substrates of interest can be
measured in hepatocytes alone, or in hepatocytes plus canalicular networks. This allows
determination of the in vitro intrinsic biliary clearance. To date, most SC experiments have
been conducted using rat hepatocytes. 93,96–100 Recently, SC human hepatocytes also have
been characterized; uptake and efflux transport proteins are expressed, properly localized on
the apical and basolateral membranes and functional.91,101 Since SC human hepatocytes also
retain metabolic capabilities, this model allows for investigation of the interplay between many
of the processes that take place in vivo. Additionally, these cells can be maintained in culture
for several days allowing for the study of drug interactions involving induction mechanisms.
Human hepatocytes are not readily available and are associated with high costs. Furthermore,
each culture is performed with cells from a single donor reflecting the inherent variability
among donors in protein expression, function, and canalicular network formation. SC human
hepatocytes serve as a unique, comprehensive tool to investigate hepatobiliary transport
mechanisms.
ii. Suspended Hepatocytes—Viability of primary hepatocytes can be maintained for
several hours in suspension when supplemented with appropriate culture media and oxygen.
Fresh or cryopreserved rat and human hepatocytes have been used extensively to determine
the hepatic metabolic clearance of drugs. 102,103 Suspended hepatocytes are a useful tool to
characterize hepatic uptake and metabolism processes and inhibition studies can be perfomed
with this system. However, due to the limited viability of these cells, it is not possible to study
induction processes.104–106 Additionally, internalization of canalicular transport proteins
during collagenase perfusion limits the use of suspended hepatocytes to predict an overall value
for biliary clearance when transport into bile is important.
iii. Vectorial Transport Using Polarized Cell Lines—The Madin Darby Canine Kidney,
strain II (MDCKII) cells are polarized cells that have been used extensively to express various
combinations of recombinant uptake and efflux transport proteins. Initially, MDCKII cells
transfected with different combinations of a single basolateral uptake and a single canalicular
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efflux pump were established.107–109 More recently, MDCKII cells transfected with a single
efflux pump (MRP2/ABCC2) and three basolateral uptake transport proteins (OATP1B1/
SLCO1B1, OATP1B3/SLCO1B3 and OATP2B1/SLCO2B1) have been established in an
attempt to mimic vectorial transport processes in human liver.110 The combination of
quadruple, double and single transfected cells is very useful for determining the contribution
of individual transport proteins to vectorial transport processes. These cell lines can be
transfected with transport proteins of interest, grown on a permeable membrane, and used to
study the transcellular passage of selected substrates. Many model substrates have been studied
using MDCK cells, and correlated with biliary clearance values obtained from rats in vivo.
108 Although the polarized transfected cell systems are powerful tools for studying vectorial
transport, they lack a full complement of transport proteins, metabolic enzymes and co-factors
present in hepatocytes, and expression levels of transport proteins may not be comparable to
hepatocytes in vivo. These issues must be considered in data interpretation and when
extrapolating to in vivo hepatic or biliary clearance values. Nevertheless, transfected systems
are simple to use and more readily available than primary human hepatocytes and are useful
as a high-throughput screening tool.
iv. Whole Cells and Membrane Vesicles—Whole cell expression systems such as
Xenopus laevis oocytes or immortalized cell lines transfected with the transporter of interest
are ideal tools when functional studies of the kinetics of transport for individual transport
proteins are needed.111 Such expression systems have been used extensively in the literature
to demonstrate substrate specificity and for functional characterization of mutant proteins, such
as genetic polymorphisms.112,113 Although oocytes are a transient expression system and
need to be injected individually with cRNA of the protein of interest, oocytes often are used
to study uptake processes. The commercial availability of this model facilitates their use for
transport studies.114 These expression systems are more applicable to studying the effect of
genetic diseases and the molecular mechanisms of transport than for the determination of
hepatobiliary clearance.115 Because of technical difficulties in loading whole cells with a
substrate of interest prior to measuring efflux, these models are more suitable for the study of
uptake transport proteins. To circumvent this issue, the double transfected MDCKII cells have
been used, or more commonly, efflux transport processes have been studied with inside-out
membrane vesicles. Such vesicles can be prepared from primary hepatocytes or from cell lines
transfected with a transport protein of interest. Basolateral and apical membrane vesicles
prepared from polarized cells such as primary hepatocytes can be isolated through various
centrifugation steps and membrane fractions enriched in basolateral or canalicular transporters
can be used to investigate drug transport and transport inhibition.116,117 Canalicular vesicles
are more commonly prepared from rat than human hepatocytes due to limited human tissue
availability. However, several recent studies have used canalicular membrane vesicles isolated
from human hepatocytes.117–119 Membrane vesicles prepared from primary hepatocytes have
distinct advantages over transfected systems: the native membrane environment is in place
during isolation from the other cellular components, and all the hepatic transport systems are
present. Membrane vesicles can be prepared, stored frozen, and used as needed; however,
isolation of basolateral and canalicular fractions is labor intensive and complete purity is never
achieved.
Membrane vesicles prepared from cell lines transiently and stably expressing membrane
proteins of interest have been used extensively to characterize polymorphisms, substrate
specificity and structure-function relationships of efflux transport proteins.120–122 The
expression systems used are many (insect cells: e.g., Sf9 cells 123,124; mammalian cells: e.g.
HEK293 cell line 125) and expression of endogenous transporters may vary. The background
activity of membrane vesicles must be accounted for by performing control experiments in
untransfected cells; moreover, post-translational protein modifications may be different
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depending on the host cells and may affect the affinity of the transport protein for the substrate
of interest.
CONCLUSIONS
Novel and important technologies for evaluation of biliary excretion and the related
toxicological/pharmacological issues derived from drug-drug interactions at the hepatobiliary
transport level are under development. Currently, several in vitro models are used as screening
tools in drug discovery and early development to eliminate molecules that present challenges
in this particular aspect of disposition.126–128 Comparison of results obtained using in vitro
systems to data generated in vivo in humans would be extremely beneficial to substantiate in
vitro observations. Unfortunately, information on in vivo biliary excretion of drugs is not
readily available, and studies in volunteers will continue to be challenging and limited to few
subjects. However, the findings of these studies can be extremely valuable, not only to explain
results obtained using in vitro systems, but also to determine the importance of biliary excretion
and enterohepatic recirculation in the overall disposition of drugs.
In the future, it is possible that a more systematic comparison between in vivo and in vitro
hepatobiliary clearance will confirm the accuracy of in vitro scaled predictions, and allow the
development of accurate models to predict drug disposition in humans with a higher degree of
confidence. We believe that this combination of tools, together with extensive use of
mathematical modeling and simulations, will not only improve our understanding of drug
disposition, but will also help predict drug-drug interactions and/or the impact of genetic
polymorphisms on drug exposure and toxicity.
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Macro-anatomy of the hepatobiliary system: bile flow into the gallbladder is facilitated by
lower internal pressure when compared to the rest of the biliary tract (pressure values are in
parenthesis40). Water and solutes are reabsorbed within the gallbladder.
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Figure 2. Micro-anatomy of the hepatobiliary tract
(A) At the cellular level, hepatocytes are organized in cords and bathed by sinusoidal blood
from the basolateral side; the canalicular membranes form the bile canaliculi. Bile flows in the
opposite direction to blood and drains into bile ducts
(B) An enlarged view of two hepatocytes from Figure A. Transport proteins are involved in
the uptake and excretion of endogenous substances and xenobiotics into blood and bile. Filled
symbols represent unidirectional primary active transport by ATP-binding cassette (ABC)
transport proteins (Pgp, ABCB1; BSEP, ABCB11; BCRP, ABCG2; MRP2, ABCC2; MRP3,
ABCC3; MRP4, ABCC4; MRP5, ABCC5; MRP6, ABCC6; ABCG5, ABCG5; ABCG8,
ABCG8). Open symbols represent transport by members of the solute carrier protein families
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including the SLC family (OAT2, SLC22A7; OCT1, SLC22A1; NTCP, SLC10A1) and the
SLCO family (OATP1B1, SLCO1B1; OATP1B3, SLCO1B3; OATP1A2, SLC01A2;
OATP2B1, SLCO2B1). Each functional hepatocyte contains all the transport proteins depicted
in this figure. Adjacent hepatocytes form tight junctions (TJ) to seal the canalicular domain
from the basolateral domain.
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